Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CLK1 | P49759 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366426 | 0.87 | NOS2 (0.50) | NPC1RAB9AHSD17B10TP53KDM4E | |
| SCHEMBL21780744 | 0.85 | NPC1 (0.47) | NPC1RAB9AHSD17B10TP53KDM4E | |
| SCHEMBL1488919 | 0.84 | NPC1 (0.43) | NPC1RAB9AHSD17B10TP53KDM4E | |
| SCHEMBL2085379 | 0.84 | NPC1 (0.43) | NPC1RAB9AHSD17B10TP53KDM4E | |
| SCHEMBL7672592 | 0.84 | NPC1 (0.46) | NPC1RAB9AHSD17B10TP53KDM4E | |
| SCHEMBL2441387 | 0.82 | HSD17B10 (0.58) | NPC1RAB9AHSD17B10TP53KDM4E | |
| SCHEMBL27279821 | 0.81 | NPC1 (0.41) | NPC1RAB9AHSD17B10TP53KDM4E | |
| SCHEMBL2437800 | 0.80 | NPC1 (0.55) | NPC1RAB9AHSD17B10TP53KDM4E | |
| SCHEMBL28743352 | 0.79 | POLB (0.64) | NPC1RAB9AHSD17B10TP53KDM4E | |
| SCHEMBL7320659 | 0.78 | PGR (0.56) | NPC1RAB9AHSD17B10TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9635857-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| CN-102633730-A | Substituted piperazines as cb1 antagonists | SCHERING CORP | 2012-08-15 | — | — | CN | disclosed |
| CN-102558075-A | Substituted piperazines as CB1 antagonists | SCHERING CORP | 2012-07-11 | — | — | CN | disclosed |
| CN-101115726-A | Substituted piperazines as cb1 antagonists | SCHERING CORP (US) | 2008-01-30 | — | — | CN | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| US-6077853-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0951285-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5939439-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998029119-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MRPS17, TAOK1, TAOK3 | NPC1 4172/4885RAB9A 1095/4885HSD17B10 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.